Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

ABSTRACT: Although the introduction of novel targeted agents has improved patient outcomes in several human cancers, no such advance has been achieved in muscle-invasive bladder cancer (MIBC). However, recent sequencing efforts have begun to dissect the complex genomic landscape of MIBC, revealing distinct molecular subtypes and offering hope for implementation of targeted therapies. Her2 (ERBB2) is one of the most established therapeutic targets in breast and gastric cancer but agents targeting Her2 have not yet demonstrated anti-tumor activity in MIBC. Through an integrated analysis of 127 patients from three centers, we identified alterations of Her2 at the DNA, RNA and protein level, and demonstrate that Her2 relevance as a tumor driver likely may vary even within ERBB2 amplified cases. Importan

SUBMITTER: Kiss B 

PROVIDER: S-EPMC5311866 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature